Risperidone-induced metabolic dysfunction is attenuated by Curcuma longa extract administration in mice

• Published in: Metabolic brain disease 2018-02, Vol.33 (1), p.63-77
• Main Authors: Auger, Florent, Martin, Françoise, Pétrault, Olivier, Samaillie, Jennifer, Hennebelle, Thierry, Trabelsi, Mohamed-Sami, Bailleul, François, Staels, Bart, Bordet, Régis, Duriez, Patrick
• Format: Article
• Language: English
• Subjects: Abnormalities; Adipose tissue; Animals; Antipsychotics; Biochemistry; Biomedical and Life Sciences; Biomedicine; Blood Glucose - metabolism; Blood pressure; Body fat; Body weight; Body weight gain; Cholesterol; Curcuma - drug effects; Curcuma longa; Curcumin; Curcumin - pharmacology; Diet; Fatty Liver - drug therapy; Fatty Liver - metabolism; Female; Food intake; Fuel consumption; Glucose; Glucose metabolism; Glucose tolerance; Hepatotoxicity; High density lipoprotein; Hyperglycemia; Hypertension; Hypertriglyceridemia; Inflammation; Injection; Intolerance; Life Sciences; Lipid metabolism; Lipid Metabolism - drug effects; Lipids; Liver - drug effects; Liver - metabolism; Metabolic Diseases; Metabolic syndrome; Metabolism; Mice; Mice, Inbred C57BL; Neurology; Neurosciences; NF-κB protein; Oncology; Original Article; Overweight; Oxidative Stress - drug effects; Plant Extracts - pharmacology; Risperidone; Risperidone - pharmacology; Rodents; Steatosis; Synaptotagmin; Weight reduction
• ISSN: 0885-7490; 1573-7365
• DOI: 10.1007/s11011-017-0133-y

Antipsychotics, such as risperidone, increase food intake and induce alteration in glucose and lipid metabolism concomitantly with overweight and body fat increase, these biological abnormalities belong to the metabolic syndrome definition (high visceral adiposity, hypertriglyceridemia, hyperglycemia, low HDL-cholesterol and high blood pressure). Curcumin is a major component of traditional turmeric ( Curcuma longa ) which has been reported to improve lipid and glucose metabolism and to decrease weight in obese mice. We questioned the potential capacity of curcumin, contained in Curcuma longa extract (Biocurcuma™), to attenuate the risperidone-induced metabolic dysfunction. Two groups of mice were treated once a week, for 22 weeks, with intraperitoneal injection of risperidone (Risperdal) at a dose 12.5 mpk. Two other groups received intraperitoneal injection of the vehicle of Risperdal following the same schedule. Mice of one risperidone-treated groups and of one of vehicle-treated groups were fed a diet with 0.05% Biocurcuma™ (curcumin), while mice of the two other groups received the standard diet. Curcumin limited the capacity of risperidone to reduce spontaneous motricity, but failed to impede risperidone-induced increase in food intake. Curcumin did not reduce the capacity of risperidone to induce weight gain, but decreased visceral adiposity and decreased the risperidone-induced hepatomegaly, but not steatosis. Furthermore, curcumin repressed the capacity of risperidone to induce the hepatic over expression of enzymes involved in lipid metabolism (LXRα, FAS, ACC1, LPL, PPARγ, ACO, SREBP2) and decreased risperidone-induced glucose intolerance and hypertriglyceridemia. Curcumin decreased risperidone-induced increases in serum markers of hepatotoxicity (ALAT, ASAT), as well as of one major hepatic pro-inflammatory transcription factor (NFκB: p105 mRNA and p65 protein). These findings support that nutritional doses of curcumin contained in Curcuma longa extract are able to partially counteract the risperidone-induced metabolic dysfunction in mice, suggesting that curcumin ought to be tested to reduce the capacity of risperidone to induce the metabolic syndrome in human.